Literature DB >> 3191938

Intra- and inter-subject variation in the pharmacokinetics of indoramin and its 6-hydroxylated metabolite.

D M Pierce1, S M Abrams, R A Franklin.   

Abstract

Intra- and inter-subject variation in the kinetics of indoramin and its active metabolite 6-hydroxyindoramin have been studied in 5 young, healthy, male volunteers administered a single oral dose of the drug on 5 separate occasions. Inter-subject variation represented the main source of variability in indoramin plasma concentrations with, for example, the between-subjects sum of squares (a measure of the contribution to the total variability) representing around 97% of the total sum of squares for Cmax and AUC (0-24). Intra-subject and inter-subject coefficients of variation (C.V.s) were circa 20% and 100% respectively for both these parameters. Variability in 6-hydroxyindoramin concentrations was much lower and was approximately equally derived from intra- and inter-subject variation, with the C.V.s being approximately 44% for both Cmax and AUC (0-24). The results imply that the kinetic behaviour of indoramin within an individual will prove relatively consistent, despite widespread inter-subject variation, once an appropriate dosage regime has been established.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3191938     DOI: 10.1007/bf00609252

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  8 in total

1.  Pharmacokinetics and systemic availability of the antihypertensive agent indoramin and its metabolite 6-hydroxyindoramin in healthy subjects.

Authors:  D M Pierce; S M Abrams; R A Franklin
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

2.  The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine.

Authors:  D M Pierce; S E Smith; R A Franklin
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

3.  Pharmacokinetics of indoramin and its 6-hydroxylated metabolite after repeated oral dosing.

Authors:  D M Pierce; S J Warrington; R A Franklin
Journal:  Biopharm Drug Dispos       Date:  1988 Mar-Apr       Impact factor: 1.627

4.  Pharmacokinetics of intravenous indoramin in middle-aged male and female volunteers.

Authors:  H M Norbury; R A Franklin; P K Marrott; S J Warrington
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Pharmacokinetics of indoramin in man.

Authors:  G H Draffan; P J Lewis; J L Firmin; T W Jordan; C T Dollery
Journal:  Br J Clin Pharmacol       Date:  1976-06       Impact factor: 4.335

6.  Pharmacokinetics of oral indoramin.

Authors:  G N Volans; D Jeffereys; A N Latham; T Frost
Journal:  Curr Med Res Opin       Date:  1982       Impact factor: 2.580

7.  Determination of therapeutic concentrations of indoramin by liquid chromatography with fluorimetric detection.

Authors:  A J Swaisland
Journal:  Analyst       Date:  1981-06       Impact factor: 4.616

8.  Pharmacokinetics of oral indoramin in elderly and middle-aged female volunteers.

Authors:  H M Norbury; R A Franklin; P K Marrott; S J Warrington
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

  8 in total
  1 in total

Review 1.  Clinical pharmacokinetics of vasodilators. Part II.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-07       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.